Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALBENZA vs ERGAMISOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.
Levamisole is an anthelmintic and immunomodulator. It acts as a nicotinic acetylcholine receptor agonist at the neuromuscular junction in nematodes, causing spastic paralysis. Its immunomodulatory effects are thought to involve stimulation of T-cell activation and phagocytosis.
FDA-approved: Hydatid disease (Echinococcus granulosus) and neurocysticercosis (Taenia solium).,Off-label: Ascariasis, trichuriasis, hookworm infections, enterobiasis, strongyloidiasis, cutaneous larva migrans, giardiasis, microsporidiosis, and other parasitic infestations.
Adjuvant therapy in combination with fluorouracil for the treatment of Dukes' C colon cancer (FDA-approved, now discontinued),Off-label: treatment of steroid-resistant nephrotic syndrome in children, and as an adjuvant in melanoma and other cancers
400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.
150 mg orally once daily
Terminal elimination half-life of albendazole sulfoxide (active metabolite) is 8-12 hours; albendazole itself has a very short half-life (<1 hour) due to extensive first-pass metabolism.
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-12 hours) and renal impairment (increase by 1.5- to 2-fold).
Primarily metabolized by hepatic microsomal enzymes, specifically to albendazole sulfoxide (active metabolite) via CYP3A4 and possibly other CYP isoforms. Further metabolized to albendazole sulfone (inactive) and other metabolites.
Hepatic metabolism primarily via CYP450 enzymes (CYP2B6 and CYP3A4) to active metabolites. Levamisole undergoes extensive biotransformation to its major metabolites, p-hydroxy-levamisole and levamisole sulfoxide.
Primarily biliary/fecal (less than 2% renal as unchanged drug and metabolites; most eliminated via bile into feces as metabolites).
Renal (parent drug and metabolites): ~70% in urine; Fecal: ~25% primarily as metabolites; <5% unchanged in urine.
Albendazole: ~70% bound to plasma proteins (mainly albumin). Albendazole sulfoxide: ~70% bound.
20-30%, primarily to albumin.
Albendazole sulfoxide: 0.8-1.2 L/kg, indicating extensive tissue distribution including bile and CSF.
1.0-1.5 L/kg; indicates extensive tissue distribution, including penetration into liver and kidneys.
Oral: Poor bioavailability (~5-10%) of parent drug due to extensive first-pass metabolism; enhanced (up to 5-fold) with high-fat meal. Not administered parenterally.
Oral: 40-60% (extensive first-pass metabolism).
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (Cr Cl <30 m L/min); use with caution.
GFR 30-60 m L/min: no adjustment; GFR <30 m L/min: not recommended
Contraindicated in patients with known cirrhosis (Child-Pugh C). For mild to moderate hepatic impairment (Child-Pugh A or B), monitor liver function; dose adjustment not established.
Child-Pugh A: no adjustment; Child-Pugh B or C: avoid use
For children ≥2 years: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis. For children <2 years: not recommended.
2.5 mg/kg orally once daily; maximum 150 mg daily
No specific dose adjustment recommended; use with caution due to potential hepatic and renal decline. Monitor for adverse effects.
No specific adjustment; monitor for renal function and potential QT prolongation
NOT FDA APPROVED FOR ANY INDICATION IN THE UNITED STATES. (Note: This warning applies as Albendazole is not FDA-approved for use in the US; however, it is marketed elsewhere. In the US, it is available under an investigational protocol or as a compounded product.)
None specifically required for ergamisol (levamisole). However, use of levamisole as an immunomodulator has been associated with agranulocytosis and other severe hematologic reactions.
Bone marrow suppression: Monitor blood counts regularly; risk of agranulocytosis, pancytopenia.,Hepatotoxicity: Elevation of liver enzymes; contraindicated in patients with hepatic disease or abnormal liver function tests.,Neurotoxicity: Risk of seizures, especially in neurocysticercosis due to inflammatory response to dying parasites.,Carcinogenicity: Long-term use associated with increased risk of tumors in animal studies.,Pregnancy: Category D (positive evidence of human fetal risk); avoid use in pregnant women or those likely to become pregnant.
Agranulocytosis (may occur weeks after initiation and is reversible upon discontinuation), hemolytic anemia (especially in patients with G6PD deficiency), neurologic effects (seizures, dizziness, headache), hepatotoxicity, and hypersensitivity reactions.
Hypersensitivity to albendazole or benzimidazole compounds.,Pregnancy (Category D) and lactation.,Pre-existing hepatic disease or unexplained liver function test abnormalities.,Bone marrow depression or severe neutropenia.
Known hypersensitivity to levamisole; patients with a history of agranulocytosis induced by levamisole; concomitant use with alcohol (disulfiram-like reaction); caution in patients with hepatic or renal impairment.
Albendazole absorption is enhanced by fatty foods; a high-fat meal increases plasma concentration of the active metabolite albendazole sulfoxide by up to 5-fold. Avoid grapefruit juice as it may alter metabolism via CYP3A4 inhibition. Fatty meals are recommended to maximize efficacy.
Avoid alcohol during therapy due to potential disulfiram-like reaction (nausea, vomiting, flushing). No specific food restrictions; maintain adequate hydration. Grapefruit juice may inhibit CYP2C19 metabolism, potentially increasing levamisole levels; consider avoidance.
Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of congenital malformations when used during pregnancy, including craniofacial defects and limb abnormalities. Use is not recommended in women who are or may become pregnant.
Ergamisole (levamisole) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses comparable to human doses. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. In first trimester, avoid use; second and third trimester, use with caution if indicated.
Albendazole is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 0.1. Due to potential adverse effects in nursing infants (e.g., bone marrow suppression, hepatic effects), caution is advised. The manufacturer recommends discontinuing breastfeeding or the drug, taking into account the importance of the drug to the mother.
Levamisole is excreted in human milk in low amounts; M/P ratio is not established. Because of potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No specific dosing adjustments for pregnancy are established. Use is contraindicated in pregnancy due to teratogenicity. If treatment is necessary, avoid during first trimester and use the lowest effective dose for the shortest duration under strict medical supervision. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered metabolism) may require therapeutic drug monitoring if available.
Pharmacokinetics in pregnancy are not well characterized. No specific dose adjustments are recommended; however, due to potential for altered metabolism, use lowest effective dose and monitor maternal toxicity closely.
Albendazole is a broad-spectrum anthelmintic effective against intestinal and tissue nematodes, cestodes, and some protozoa. It is poorly absorbed orally; co-administration with a fatty meal significantly increases bioavailability (up to 5-fold). Monitor liver function tests periodically due to risk of hepatotoxicity. Contraindicated in pregnancy (category C) and in patients with known hypersensitivity. For neurocysticercosis, concomitant corticosteroids and antiepileptics are often required to manage inflammatory reactions. May cause bone marrow suppression; obtain CBC at baseline and periodically. Dose adjustment not needed in renal impairment but caution in hepatic impairment.
Levamisole (ERGAMISOL) is primarily used as an immunomodulator in adjuvant therapy for stage III colon cancer after surgical resection. It is often combined with fluorouracil. Monitor for agranulocytosis, especially in patients with poor metabolizer status of CYP2D6. Agranulocytosis can occur weeks to months after initiation; obtain baseline CBC and repeat periodically. Levamisole can cause a metallic taste and reversible ANCA-positive vasculitis. Avoid in patients with known hypersensitivity or bone marrow depression.
Take with a high-fat meal to increase absorption.,Complete the full course of therapy even if symptoms improve.,Use effective contraception during treatment and for at least 1 month after the last dose.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, right upper quadrant pain.,May cause dizziness; avoid driving or operating machinery if affected.,Notify your healthcare provider if you experience persistent sore throat, fever, or unusual bleeding/bruising.
Take levamisole exactly as prescribed, usually for 3 days every 2 weeks for 1 year. Do not miss doses.,Report any signs of infection (fever, sore throat, mouth sores) immediately as it can lower white blood cell count.,You may experience a metallic taste; this is harmless and may resolve with time.,Avoid alcohol consumption as it may increase risk of adverse effects.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Do not take any other medications or supplements without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALBENZA vs ERGAMISOL, answered by our medical review team.
ALBENZA is a Anthelmintic that works by Albendazole is a benzimidazole carbamate that inhibits tubulin polymerization by binding to the colchicine site of β-tubulin, disrupting microtubule formation. This leads to impaired uptake of glucose and depletion of glycogen stores, resulting in immobilization and death of susceptible helminths.. ERGAMISOL is a Anthelmintic Immunomodulator that works by Levamisole is an anthelmintic and immunomodulator. It acts as a nicotinic acetylcholine receptor agonist at the neuromuscular junction in nematodes, causing spastic paralysis. Its immunomodulatory effects are thought to involve stimulation of T-cell activation and phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALBENZA and ERGAMISOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALBENZA is: 400 mg orally twice daily for 60 days for neurocysticercosis; 400 mg orally once daily for 3 days for pinworm; 400 mg orally once daily for 3 days for hookworm, roundworm, whipworm; 400 mg orally twice daily for 3 days for tapeworms; 400 mg orally twice daily for 7 days for giardiasis.. The standard adult dose of ERGAMISOL is: 150 mg orally once daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALBENZA and ERGAMISOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALBENZA is classified as Category C. Albendazole is contraindicated in pregnancy, especially during the first trimester. It has been shown to be embryotoxic and teratogenic in animals. In humans, there are reports of . ERGAMISOL is classified as Category C. Ergamisole (levamisole) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxicity and teratogenicity at doses comparable to human doses. There are no adeq. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.